A5000582338- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Meta-analysis and systematic reviews
- HIV Research and Treatment
- Clinical practice guidelines implementation
- Tuberculosis Research and Epidemiology
- Ethics in Clinical Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Intramuscular injections and effects
- PARP inhibition in cancer therapy
- Ear Surgery and Otitis Media
- Hospital Admissions and Outcomes
- vaccines and immunoinformatics approaches
- Mycobacterium research and diagnosis
- Tracheal and airway disorders
- Delphi Technique in Research
- Antibiotics Pharmacokinetics and Efficacy
- Computational Drug Discovery Methods
- Pneumocystis jirovecii pneumonia detection and treatment
- Respiratory viral infections research
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare Policy and Management
- Pharmaceutical studies and practices
Middlesex University
2023
GlaxoSmithKline (United Kingdom)
2019-2022
GlaxoSmithKline (United States)
2022
Age UK
2022
GlaxoSmithKline (Netherlands)
2022
Public Health England
2016-2020
Imperial College London
2012-2015
London School of Hygiene & Tropical Medicine
2012-2014
University of KwaZulu-Natal
2013-2014
Stellenbosch University
2014
Deaths in HIV-positive people have decreased since the introduction of highly active antiretroviral therapy (HAART) 1996. Fewer AIDS-related deaths and an ageing cohort resulted increase proportion HIV patients dying from non-AIDS-related disorders. Here we describe mortality causes death diagnosed with HAART era compared general population.In this observational analysis, linked data collected by Public Health England (PHE) for individuals aged 15 years older, Wales 1997 to 2012, Office...
An urgent UK investigation was launched to assess risk of invasive Mycobacterium chimaera infection in cardiothoracic surgery and a possible association with cardiopulmonary bypass heater-cooler units following alerts Switzerland The Netherlands.Parallel investigations were pursued: (1) identification bypass-associated M. through national laboratory hospital admissions data linkage; (2) cohort study patient risk; (3) microbiological aerobiological heater-coolers situ under controlled...
This first-time-in-human (FTIH) study evaluated the safety, tolerability, pharmacokinetics, and food effect of single repeat oral doses GSK3036656, a leucyl-tRNA synthetase inhibitor. In part A, GSK3036656 5 mg (fed fasted), 15 mg, 25 placebo were administered. B, administered for 14 days once daily. showed dose-proportional increase following single-dose administration after dosing days. The maximum concentration drug in serum (Cmax) area under concentration-time curve from 0 h to end...
Objective To determine the frequency and patterns of acquired antiretroviral drug resistance in a rural primary health care programme South Africa. Design Cross-sectional study nested within HIV treatment programme. Methods Adult (≥18 years) HIV-infected individuals initially treated with first-line stavudine- or zidovudine-based therapy (ART) regimen evidence virological failure (one viral load >1000 copies/ml) were enrolled from 17 clinics. Genotypic testing was performed using in-house...
Objectives Weekend admissions have been shown to be associated with an increased risk of mortality compared weekday for many diagnoses. We analysed emergency department within the Scottish National Health Service investigate whether is in case weekend admissions. Design A cohort study. Setting Scotland (NHS) departments. Participants 5 271 327 between 1999 and 2009. included all patients admitted via departments recorded Morbidity Records (SMR01) NHS, whom complete demographic data were...
Abstract Background Previous studies have suggested that there may be an association between some immune-mediated diseases and risk of tuberculosis (TB). Methods We analyzed a database linked statistical records hospital admissions death certificates for the whole England (1999 to 2011), similar (the Oxford Record Linkage Study (ORLS)) region southern in earlier period. Rate ratios TB were determined, comparing disease cohorts with comparison cohorts. Results In all-England dataset,...
<ns4:p><ns4:bold>Background</ns4:bold>: An important principle in the good conduct of clinical trials is that a summary trial protocol, with pre-defined primary outcome, should be freely available before study commences. The registry ClinicalTrials.gov provides one method doing this, and once registered, any changes made to outcome are documented. objectives this were: assess proportion registered on had changed; when was changed relation listed start end dates whether change...
Convenient administration of coronavirus disease 2019 (COVID-19) treatment in community settings is desirable. Sotrovimab a pan-sarbecovirus dual-action monoclonal antibody formulated for intravenous (IV) or intramuscular (IM) early mild/moderate COVID-19.
ClinicalTrials.gov identifier, NCT05280717.
Objective To present the results of a 5-year longitudinal study in pediatric population undergoing surgery for extensive cholesteatoma using canal wall down (CWD) approach with obliteration. Study Design Prospective study. Patients Children (<16 years) (58 ears) between 1999 and 2013. Interventions Therapeutic. Setting District general hospital. Main Outcome Measures (1) Residual, recurrence, recidivist rates at 5 years post-surgery; (2) postoperative hearing; (3) waterproofing ear; (4)...
Abstract Purpose Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have impacted the in vitro activity of sotrovimab 500 mg, with reduced fold change EC 50 for Omicron BA.2 sublineage and onward. The correlation between this reduction clinical efficacy outcomes is unknown. In absence trials assessing against emerging variants, real-world evidence becomes a critical source information. A systematic literature review (SLR) published observational studies was...
HIV treatment guidelines have traditionally recommended that all HIV-positive individuals are tested for evidence of drug resistance prior to starting ART. Testing reverse transcriptase inhibitors and PIs is well established in routine care. However, testing integrase strand transfer inhibitor (InSTI) less consistent.To inform by determining the prevalence InSTI a national cohort recently infected individuals.Recent (within 4 months) HIV-1 infections were identified using Recent Infection...
Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression hospitalization or death in non-hospitalized high-risk patients with mild moderate coronavirus disease 2019 following either intravenous (i.v.) intramuscular (i.m.) administration. Population pharmacokinetic (PopPK) and exposure-response (ER) analyses were performed characterize single dose sotrovimab pharmacokinetics (PK) the relationship between exposure response (probability of progression),...
We and others have shown a significant proportion of interventional trials registered on ClinicalTrials.gov their primary outcomes altered after the listed study start completion dates. The objectives this were to investigate whether changes made are associated with likelihood reporting statistically outcome ClinicalTrials.gov.A cross-sectional analysis all clinical as 20 November 2014 was performed. main any change initially time in relation trial end date.13,238 completed that also had...
Antiretroviral drug resistance is becoming increasingly common with the expansion of human immunodeficiency virus (HIV) treatment programmes in high prevalence settings. Genotypic testing could have benefit guiding individual-level decisions but successful models for delivering low- and middle-income countries not been reported. An HIV Treatment Failure Clinic model was implemented within a large primary health care programme northern KwaZulu-Natal, South Africa. offered to adults (≥16...
<ns4:p><ns4:bold>Background</ns4:bold>: We and others have shown a significant proportion of interventional trials registered on ClinicalTrials.gov their primary outcomes altered after the listed study start completion dates. The objectives this were to investigate whether changes made are associated with likelihood reporting statistically outcome ClinicalTrials.gov.</ns4:p><ns4:p><ns4:bold>Methods</ns4:bold>: A cross-sectional analysis all clinical as 20 November 2014 was performed. main...
Abstract Background Five hundred milligrams of intravenous (IV) sotrovimab has been shown to be well tolerated and efficacious against pre-Omicron strains in treating patients with mild moderate coronavirus disease 2019 (COVID-19) at high risk for progression. Methods This was an open-label, single-arm substudy phase 3 COMET-TAIL (NCT04913675) assessing the safety tolerability a 2000 mg IV dose sotrovimab. Symptomatic (aged ≥18 years) COVID-19 progression were enrolled from June 30 through...
Substantial amounts of data have been generated from patient management and academic exercises designed to better understand the human immunodeficiency virus (HIV) epidemic design interventions control it. A number specialized databases manage huge sets HIV cohort, vaccine, host genomic drug resistance studies. Besides cohort studies, most online contain limited curated are thus sequence repositories. has shown a great potential derail progress made far through antiretroviral therapy. Thus,...
Tuberculosis (TB) is common in people living with HIV, leading to worse clinical outcomes including increased mortality. We investigated risk factors for developing TB following HIV diagnosis.Adults aged at least 15 years first presenting health services care England, Wales or Northern Ireland from 2000 2014 were identified national surveillance data and linked data.We calculated incidence rates occurring more than 91 days after diagnosis using multivariable Poisson regression.A total of 95...
Sotrovimab 500 mg administered by a single intravenous (IV) infusion has been granted special approval for emergency use in Japan treatment of SARS-CoV-2 infection adults and children aged ≥ 12 years weighing 40 kg. This Phase 1, single-dose study investigated the pharmacokinetics, safety, tolerability IV or intramuscular (IM) sotrovimab doses versus placebo healthy Japanese Caucasian volunteers. was two-part, randomized, placebo-controlled, single-blind study. In Part participants received...
Abstract Background Sotrovimab (VIR-7831) is an engineered human monoclonal antibody targeting a conserved region of the SARS-CoV-2 spike protein; it has been shown to have favorable safety profile and be effective for early treatment high-risk COVID-19 patients. The COMET-TAIL phase 3 study evaluated sotrovimab administered intravenously (IV) or intramuscularly (IM) participants with mild moderate who are at high risk disease progression. Methods Between June August 2021, 973 were...